Thoracic Surgery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The thoracic surgery devices market size is projected to be USD 12.15 billion in 2025, USD 12.95 billion in 2026, and reach USD 18.36 billion by 2031, growing at a CAGR of 7.23% from 2026 to 2031. This report is Segmented by Procedure Type (Open, VATS, Robotic-Assisted, Endoscopic), Product Type (Instruments, Endoscopes/Imaging, Energy/Stapling, Robotic Platforms), Indication (Lung Cancer, Esophageal Cancer, Pneumothorax, Mediastinal Tumors, Hyperhidrosis), End User (Hospitals, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Thoracic Surgery Devices Market Trends and Insights

Rising Lung Cancer Screening and Earlier Surgical Referral

Expanded lung cancer screening programs are producing more early-stage diagnoses, and that directly raises the number of patients who move into surgical pathways in the thoracic surgery device market. At OSF HealthCare, an AI-assisted multistep screening program increased the institutional screening rate from 18.2% in 2020 to 42.8% by 2025, while stage I diagnoses rose from 30.9% to 44.6% over the same period. The UK NHS Lung Cancer Screening Programme reported 7,193 lung cancers diagnosed through screening by March 2025, and 63.1% of those cases were stage 1, which shows how screening can shift case mix toward earlier surgical intervention. Earlier detection also expands the volume of staging procedures, image-guided bronchoscopy, and navigational bronchoscopy, so the commercial benefit in the thoracic surgery device market extends beyond formal resection alone. That broader procedural funnel supports demand for endoscopy systems, imaging tools, and access devices as hospitals manage more nodules and more early lesions through organized thoracic pathways.

Increasing ERAS Adoption and Same-Day Recovery Pathways

Enhanced recovery pathways are helping the thoracic surgery device market move selected procedures into ambulatory and same-day discharge settings. A systematic review and meta-analysis in JTCVS Open found that Enhanced Recovery After Thoracic Surgery protocols reduced hospital length of stay by 3 days and lowered overall postoperative complications across 19 studies and 8,447 patients. A bibliometric study covering 617 publications from 2015 to 2024 across 44 countries showed that thoracic ERAS research now exceeds 100 papers annually, with China contributing 214 publications and the United States 155, which points to ongoing protocol refinement rather than isolated adoption. A 2024 real-world study on VATS day surgery for pulmonary nodule resection showed that prehabilitation, small-diameter drainage tubes, and multimodal pain management enabled faster discharge than standard care. As more centers standardize these pathways, the thoracic surgery device market gains additional volume in lower-cost settings without requiring every case to remain inside traditional inpatient referral channels. This shift also favors platforms and instruments that shorten recovery and simplify postoperative management.

Steep Surgeon Learning Curve for Advanced Thoracic Platforms

The thoracic surgery device market still faces an adoption ceiling because robotic proficiency takes much longer to build than conventional VATS capability. A nationwide population-based study across 28 Korean hospitals found a median learning curve threshold of 110 procedures, and only 8 of the 28 hospitals reached that level during the 2019 to 2022 study period. A Norwegian single-center study of 200 robotic pulmonary lobectomies found a bi-phasic learning curve, with operative time still improving after the 117th procedure and complication rates stabilizing only around the 94th case. This creates an economic trap inside the thoracic surgery device market because hospitals often commit capital before surgeons reach the efficiency needed to justify the program. The problem is sharper in Tier 2 hospitals and emerging markets where proctoring systems, fellowship pipelines, and structured robotic training are less developed. Until those support systems widen, robotic diffusion in the thoracic surgery device market will remain uneven across hospital tiers.

Other drivers and restraints analyzed in the detailed report include:

• AI-Guided Imaging and Workflow Integration
• Aging Population and Complex Comorbidity Burden
• High Capital Expenditure and Case-Volume Threshold Risk

Segment Analysis

Video-assisted thoracoscopic surgery held 49.21% of the thoracic surgery device market share in 2025, making it the largest procedure segment in the thoracic surgery device market. Its position reflects long-term clinical evidence, established training pathways, and reliable oncologic outcomes in lung resection. Penetration has already become deep in major academic centers across North America and Europe, but expansion continues in community hospitals through narrower trocars, 4K visualization, and low-pressure insufflation. Robotic-Assisted Thoracic Surgery is projected to grow at 8.23% CAGR through 2031, supported by articulated instruments, tremor filtration, and 3D optics that improve access in mediastinal and subcarinal lymph node territories.

A 2026 multicenter cohort study reported that robotic lobectomy delivered lower conversion-to-open rates and shorter postoperative stays than VATS, which strengthens the case for robotic use in higher-complexity procedures. Open Thoracic Surgery still retains a meaningful place in the thoracic surgery device market for re-operative cases, vascular invasion, and trauma, where minimally invasive access remains limited. Endoscopic Thoracic Surgery remains smaller, but it is growing as navigational bronchoscopy expands biopsy and focal ablation options for peripheral lesions that might otherwise move to resection. In Japan, reimbursement inclusion of robotic lobectomy in 2018 and segmentectomy in 2020 helped robotic thoracic surgery move from less than 1% of lung cancer procedures to more than 15% by 2025, which suggests the regional ceiling for VATS may be lower in Asia-Pacific than current shares indicate. That sequencing matters because the thoracic surgery device market often follows reimbursement expansion before broader platform adoption takes hold.

Robotic platforms held 31.83% of product type revenue in 2025, which made them the largest product segment in the thoracic surgery device market. The segment reflects the installed base effect and the premium value attached to core hardware, supporting instruments, and related software. Endoscopes and imaging systems are projected to grow at 7.28% CAGR through 2031, which makes them the fastest-moving product category in the thoracic surgery device market. Growth comes from 4K fluorescence-guided visualization, indocyanine green perfusion imaging for segmental plane mapping, and AI-enhanced overlay tools that now appear in both standalone systems and robotic towers.

Surgical instruments and accessories rise with every expansion in the robotic installed base because replacement and disposable use recur with each procedure. Energy and Stapling Devices face more pressure in standard configurations, but specialized thick-tissue reloads for hilar anatomy and dense esophageal tissue still support premium positioning. The thoracic surgery industry also shows a gradual shift toward ultrasonic energy platforms for selected lobectomy and segmentectomy steps that were once reserved for mechanical staplers. The segment mix, therefore, favors vendors that can pair core capital equipment with repeat-use accessories and imaging upgrades. That pattern keeps the thoracic surgery device market tilted toward vendors with broad portfolios, strong service coverage, and integration across visualization, access, and robotic workflows.

Complete Report Scope:

• By Procedure Type
  • Open Thoracic Surgery
  • Video-Assisted Thoracoscopic Surgery
  • Robotic-Assisted Thoracic Surgery
  • Endoscopic Thoracic Surgery
• By Product Type
  • Surgical Instruments and Accessories
  • Endoscopes and Imaging Systems
  • Energy and Stapling Devices
  • Robotic Platforms
• By Indication
  • Lung Cancer
  • Esophageal Cancer
  • Pneumothorax
  • Mediastinal Tumors
  • Hyperhidrosis
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Thoracic Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.23% of thoracic surgery device market share in 2025, which made it the largest regional segment in the thoracic surgery device market. This position is supported by a dense robotic installed base, mature ERAS adoption, and a reimbursement structure that still supports complex thoracic procedures across hospital systems. CMS policy documentation for 2026 shows DRG-based reimbursement for complex thoracic procedures under codes 163 to 165 ranging from USD 13,929 to USD 32,613 per case depending on complexity. The United States remains the main volume center in the region because it combines high procedural intensity with broad access to robotic and advanced endoscopic platforms. At the same time, the 2.5% reduction in non-time-based work RVUs for cardiothoracic surgery effective January 1, 2026 creates a near-term margin headwind that could push programs to favor time-efficient pathways and selected site migration rather than reduce procedure volumes outright.

Europe held the second-largest regional position in the thoracic surgery device market, led by Germany and the United Kingdom. The region benefits from strong thoracic center networks, but device adoption remains shaped by a more demanding compliance environment under the EU Medical Device Regulation. In 2025, Guy’s and St Thomas’ NHS Foundation Trust awarded a 7-year direct robotic thoracic surgery contract to Intuitive Surgical through the NHS Supply Chain framework, which shows how public procurement can lock in long-duration vendor relationships once compliance barriers are cleared. France, Italy, Spain, Poland, the Netherlands, and the Scandinavian countries continue to expand VATS and ERAS use within national health system constraints.

Asia-Pacific is projected to grow at 8.92% CAGR through 2031, which makes it the fastest-growing regional segment in the thoracic surgery device market. Japan has already shown how reimbursement can reshape procedure mix, with robotic-assisted thoracic surgery moving from less than 1% of lung cancer procedures in 2017 to more than 15% by 2025 after insurance inclusion widened. China is becoming the most structurally important growth engine in the thoracic surgery device market because domestic robotic brands won more than 50% of public hospital tenders in 2025, while Shanghai Pulmonary Hospital surpassed 1,000 domestic robot-assisted thoracic cases at a single center. India, South Korea, and Australia are also extending minimally invasive and robotic thoracic capacity through reimbursement expansion and high-volume oncology centers, while the Middle East and Africa and South America remain smaller but emerging destinations for investment through private hospital growth and medical tourism infrastructure.

List of Companies Covered in this Report:

• Applied Medical Resources
• Asensus Surgical
• B. Braun
• Boston Scientific
• CMR Surgical
• Conmed
• Danaher
• FUJIFILM
• Getinge
• Intuitive Surgical
• Johnson & Johnson
• Karl Storz SE and Co. KG
• Medtronic
• MicroPort
• Olympus
• Richard Wolf
• Mindray
• Smiths Group
• Stryker
• Teleflex

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support